Pharmaceutical epidemiology: Development and implementation in France;Enjeux de la pharmaco-epidemiologie en France

Presse Medicale

Volumn 28, Issue 9, 1999, Pages 493-499

  Guillemot, D ^a   Maison, P ^e   Carbon, C ^b   Bouvenot, G ^c   Imbs, J L ^d   Eschwege E ^a  

^a INSERM   (France)

^b BICHAT HOSPITAL   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d UNIVERSITÉ DE STRASBOURG   (France)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

DRUG INDUSTRY; FRANCE; HEALTH CARE ORGANIZATION; PHARMACEUTICAL CARE; REVIEW; EPIDEMIOLOGY; HUMAN; PHARMACOLOGY; PRESCRIPTION; STATISTICS;

EPIDEMIOLOGY; FRANCE; HUMANS; PHARMACOLOGY; PRESCRIPTIONS, DRUG;

EID: 0033528360     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Fayers PM, Hand DJ. Generalisation from phase III clinical trial:survival, quality of life, and healt economics. Lancet 1997 ; 150:1025-7.
2. Ström B. What is pharmacoepidemiology ? In: Strom B, ed. Pharmacoepidemiology. 2nd ed. Chichester: John Wiley & Sons Ltd; 1994:3-13.
3. e journée d'Étude de l'Association pour le développement de la pharmacologie clinique (ADPC). Paris: La lettre du pharmacologue ; 1993.
4. Walson PD. Therapeutic drug monitoring in special populations. Clin Chem 1998 ; 44:415-9.
5. Bates DW, Soldin SJ, Rainey PM, Micelli JN. Strategies for physician education in therapeutic drug monitoring. Clin Chem 1998 ; 44:401-7.
6. Tabuteau D. La sécurité sanitaire. In: Pratique SMe, ed: Berger Levrault; 1992.
7. Byington RP, Craven TE, Furberg CD, Pahor M. Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular events. Lancet 1997 ; 350:1075-6.
8. Aldreman M, Madhavan S, Cohen H. Calcium antagonist and cardiovascular events in patients with hypertension and diabetes. Lancet 1998 ; 351:216-17.
9. Simon G, Wagner E, Vonkorff M. Cost-effectiveness comparisons using "real world" randomized trials: the case of new antidepressant drugs (see comments). J Clin Epidemiol 1995 ; 48:363-73.
10. Simon GE, VonKorff M, Heiligenstein JH et al. Initial anti-depressant choice in primary care. Effectiveness and cost of fluoxetine vs tricyclic antidepressants (see comments). JAMA 1996 ; 275:1987-902.
11. Papoz L. Utilization of drug sales data for the epidemiology of chronic diseases: the example of diabetes. The EURODIAB Subarea C Study Group. Epidemiology 1993 ; 4:421-7.
12. Durrington P. Statins and Fibrates in the management of diabetic dyslepidemia. Diabetic Medicine 1997 ; 14:513-16.
13. Mikhailidis DP, Mathur S, Barradas MA, Dandona P. Bezafibrate retard in type II diabetic patients: effect on hemostasis and glucose homeostasis. J Cardiovasc Pharmacology 1990 ; 16:s26-9.
14. Bégaud B, Fourrier A. Importance de la pharmaco-épidémiologie pour l'industrie du médicament. La Lettre du Pharmacologue 1998 ; 12:156-9.
15. ARME-Pharmacovigilance. Données françaises de morbidité utiles en pharmacovigilance. Bordeaux: ARME-Pharmacovigilance; 1994:161.
16. Melnychuk D, Moride Y, Abenhaim L. Monitoring of drug utilization in public health surveillance activities: a conceptual framework. Can J Public Health 1993 ; 84:45-9.
17. Herings RM, Bakker A, Stricker BH, Nap G. Pharmaco-morbidity linkage: a feasibility study comparing morbidity in two pharmacy based exposure cohorts. J Epidemiol Community Health 1992 ; 46:136-40.
18. Miller E, Blatman B, Einarson TR. A survey of population-based drug databases in Canada. Can Med Assoc J 1996 ; 15:1855-64.
19. Tennis P, Andrews E, Bombardier C et al. Record linkage to conduct an epidemiologic study on the association of rheumatoid arthritis and lymphoma in the Province of Saskatchewan, Canada. J Clin Epidemiol 1993 ; 46:685-95.
20. Stergachis AS. Record linkage studies for postmarketing drug surveillance: data quality and validity considerations. Drug Intell Clin Pharm 1988 ; 22:157-61.
21. Crombie IK, Brown SV, Hamley JC. Postmarketing drug surveillance by record linkage in Tayside. J Epidemiol Community Health 1984 ; 38:226-31.
22. Strand M, Downey W. Health Database in Saskatchewan. In: Ström B, ed. Pharmacoepidemiology. New York: John Wiley & Sons; 1994:217-19.
23. Carson J, Strom B. Medicaid databases. In: Strom B, ed. Pharmacoepidemiology. 2nd ed. Chichester: John Wiley & Sons Ltd; 1994:29-38.
24. Tamblyn R, Lavoie G, Petrella L, Monette J. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 1995 ; 48:999-1009.
25. Leufkens H, Urquhart J. Automated Record Linkage and other Approaches to pharmacoepidemiology in the Netherland. In: Ström B, ed. Pharmacoepidemiology. New York: John Wiley & Sons; 1994:231-44.
26. Walley T, Mantgani A. The UK General Practice Research Database. Lancet 1997 ; 350:1097-9.
27. Habbick B, Baker MJ, McNutt M, Cockcroft DW. Recent trends in the use of inhaled beta 2-adrenergic agonists and inhaled corticosteroids in Saskatchewan. Can Med Assoc J 1995 ; 15:1437-43.
28. Hogan DJ, Strand LM, Lane PR. Isotretinoin therapy for acne: a population-based study. Can Med Assoc J. 1988 ; 1:47-50.
29. Ström BL, Morse ML. Use of computerized databases to survey drug utilization in relation to diagnoses. Acta Med Scand Suppl 1988 ; 721:13-20.
30. West R, Sherman GJ, Downey W. A record linkage study of valproate and malformations in Saskatchewan. Can J Public Health 1985 ; 76:226-8.
31. Garcia Rodriguez LA, Walker AM, Perez Gutthann S. Nonsteroidal antiinflammatory drugs and gastrointestinal hospitalizations in Saskatchewan: a cohort study. Epidemiology 1992 ; 3:337-42.
32. Garcia Rodriguez L, Jick H. The risk of upper gastrointestinal bleeding. 1994.
33. Guess HA, West R, Strand LM et al. Fatal upper gastrointestinal hemorrhage or perforation among users and nonusers of nonsteroidal anti-inflammatory drugs in Saskatchewan, Canada 1983. J Clin Epidemiol 1988 ; 41:35-45.
34. Garcia Rodriguez LA, Perez Gutthann S, Walker AM, Lueck L. The role of non-steroidal anti-inflammatory drugs in acute liver injury (published erratum appears in BMJ 1992 ; 305:920. BMJ 1992 ; 305:865-8.
35. Ray WA, Griffin MR, Downey W. Benzodiazepines of long and short elimination half-life and the risk of hip fracture (see comments). JAMA 1989 ; 262:3303-7
36. Suissa S, Ernst P, Boivin JF et al. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am J Respir Crit Care Med 1994 ; 149:604-10.
37. Spitzer WO, Suissa S, Ernst P et al. The use of beta-agonists and the risk of death and near death from asthma (see comments). N Engl J Med 1992 ; 327:501-6.
38. Jick H. A database worth saving. Lancet 1997 ; 350:1045-6.
39. de Pouvourville G. Differences in the approaches of the doctor, manager, politician and social scientist in health care controversies-hospital case-mix management methods: an illustration of the manager's approach in health care controversies. Soc Sci Med 1989 ; 29:341-9.
40. de Pouvourville G. Quality of care initiatives in the French context. Int J Qual Health Care 1997 ; 9:163-70.
41. Lombrail P, Minvielle E, Comar L, Gottot S. Prospective Payment Information Systems and epidemiology: a difficult link to establish. Rev Epidemiol Sante Publique 1994 ; 42:334-44.